The company reported that it plans to use its available cash, the offering’s proceeds and funds from a revolving credit facility to redeem $1 billion of outstanding 5.25% senior notes due in 2022.
Last week, Hologic said that its Brevera breast biopsy system with CorLumina imaging tech won CE Mark clearance in the E.U.
The real-time breast biopsy and verification system is designed to boost accuracy and improve the patient experience by streamlining the biopsy process, according to Hologic.
The technology combines tissue acquisition, real-time imaging, sample verification and advanced post-biopsy handling into one system.
Traditionally, patients undergoing stereotactic breast biopsy procedures remain under compression while being moved from one room to another to image and verify tissue samples. But radiologists using the Brevera system can obtain and image samples in a single room in just a few seconds, saving up to 10 minutes per patient and slashing the procedure time by up to 25%, Hologic noted.